Post-Kidney Transplantation Drug Programme
New anti-rejection drugs are developed for post-kidney transplanted patients, which have better results including longer survival of the transplanted graft kidney and fewer side effects. The side effects of traditional drugs such as growth retardation, gum hypertrophy and hairiness affect the patients' appearances and self-image which are the concerns of adolescents who may become non-compliant with drug treatment thus resulting in graft failure. These new drugs are costly but not yet offered by the Hospital Authority.
We provide at most 85% of the cost for the actual purchase of Mycophenolate Mofetil (MMF) as prescribed by the doctors. Ceiling subsidies per case per calendar year may vary. Means test on family income is required, with recommendation from both the attending doctor and medical social worker.
For details, please refer to the https://www.childrenkidneyfund.org.hk/en/services.
Attachment | Size |
---|---|
![]() | 396.78 KB |
- Home
- About Us
- Kidney Health
- Services
- Automated Peritoneal Dialysis Programme
- Travelling Allowance for Haemodialysis Treatment
- Post-Kidney Transplantation Drug Programme
- Induction Drug Treatment Subsidy for Kidney Transplantation
- Rituximab /Obinutuzumab Treatment Subsidy
- Subsidy for Sodium Zirconium Cyclosilicate (Lokelma)
- The IPNA Prof. Chiu Fellowship Fund for Paediatric Nephrology
- Support for Research & Training
- Patient and Family Activities
- Sharings
- Support Us
- Contact
- Introductory information and Photos of Activities
- Online Donation Form
- Related Links